CalciMedica Inc. (NASDAQ:CALC) Stock Short Interest Climbs 178.0%

CalciMedica Inc. (NASDAQ:CALC) was the recipient of a significant increase in short interest in October. As of October 30th, there was short interest totaling 171,388 shares, an increase of 178.0% from the October 15th total of 61,641 shares. Based on an average daily trading volume, of 96,501 shares, the days-to-cover ratio is currently 1.8 days. Currently, 3.5% of the shares of the stock are sold short.

CalciMedica Price Performance

Shares of NASDAQ CALC traded down $0.01 during midday trading on Friday, hitting $1.21. 30,708 shares of the company’s stock were exchanged, compared to its average volume of 81,136. CalciMedica has a 12-month low of $1.00 and a 12-month high of $36.00. The company has a current ratio of 4.96, a quick ratio of 5.58 and a debt-to-equity ratio of 1.63. The company has a market cap of $8.35 million, a price-to-earnings ratio of -0.27 and a beta of 0.84. The business’s fifty day moving average price is $1.54 and its two-hundred day moving average price is $3.00.

CalciMedica (NASDAQ:CALC) last announced its earnings results on Tuesday, November 10th. The company reported ($0.24) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.27) by $1.03. As a group, research analysts forecast that CalciMedica will post -1.93 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently commented on CALC shares. Guggenheim assumed coverage on shares of CalciMedica in a research note on Thursday, August 20th. They set a “buy” rating for the company. UBS Group reaffirmed a “neutral” rating on shares of CalciMedica in a report on Thursday, August 13th. HC Wainwright reiterated a “neutral” rating on shares of CalciMedica in a research note on Wednesday, July 29th. Weiss Ratings upgraded shares of CalciMedica from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 27th. Finally, Wall Street Zen cut shares of CalciMedica from a “sell” rating to a “strong sell” rating in a report on Saturday, September 12th. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $50.00.

Hedge Funds Weigh In On CalciMedica

An institutional investor recently raised its position in CalciMedica stock. Renaissance Technologies LLC raised its position in shares of CalciMedica Inc. (NASDAQ:CALC) by 45.0% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 128,075 shares of the company’s stock after purchasing an additional 39,775 shares during the period. Renaissance Technologies LLC owned approximately 0.81% of CalciMedica worth $69,000 at the end of the most recent reporting period.

CalciMedica Company Profile

CalciMedica is a clinical-stage biopharmaceutical company developing treatments for serious inflammatory and immunologic conditions. Its research focuses on calcium release-activated calcium (CRAC) channels, which play a role in immune-cell activity and inflammation. The company’s lead drug candidate, Auxora, is an investigational CRAC channel inhibitor being studied for acute inflammatory conditions, including acute pancreatitis. CalciMedica has no marketed products; its candidates remain in clinical development.